ArticleCalcified tissue international2022
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.
Article in Calcified tissue international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.Frontiers in endocrinology · 2023Trial
- Response to Letter to the Editor on "Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients".JBMR plus · 2026Article
- Osteoporosis risk in alpha and beta thalassemia: An age- and sex-specific retrospective cohort study.Archives of osteoporosis · 2026Article
- Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients.JBMR plus · 2026Article
- Cardiac Magnetic Resonance in the Assessment of Atrial Cardiomyopathy and Pulmonary Vein Isolation Planning for Atrial Fibrillation.Journal of imaging · 2025Review
- Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.Journal of endocrinological investigation · 2025Review
- A challenging convergence of conditions in a patient with thalassemia major presenting with thymoma and lymphangioleiomyomatosis: a case report.Journal of medical case reports · 2025Article
- iFGF23 Plasma Levels in Transfusion-Dependent β-Thalassemia: Insights into Bone and Iron Metabolism.Journal of clinical medicine · 2025Article
- What are the treatment options for beta-thalassemia patients with osteoporosis? A Cochrane Review summary with commentary.Journal of musculoskeletal & neuronal interactions · 2024Article
- Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Recent advancements in glucose dysregulation and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT): an update of ICET-A (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine).Acta bio-medica : Atenei Parmensis · 2023Review
- Bibliometric study on clinical research of osteoporosis in adolescents.Frontiers in public health · 2023Article
- The role of opportunistic quantitative computed tomography in the evaluation of bone disease and risk of fracture in thalassemia major.European journal of haematology · 2022Article
- Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.Acta bio-medica : Atenei Parmensis · 2022Review
- Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.British journal of haematology · 2022Article
- New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis represents a relevant cause of morbidity in adult Thalassemia Major (TM) population. Antiresorptive drugs such as bisphosphonates were demonstrated effective in preventing bone loss. Teriparatide (TP) is an anabolic agent approved for osteoporosis management in the general population, but its use has been very limited in TM patients so far. We evaluated TP efficacy and safety in TM-associated osteoporosis in real-life clinical practice. Retrospective evaluation of 11 TM patients (6 males, 5 females; mean age = 45 ± 4.38 years) with severe osteoporosis and multiple fractures under TP treatment. Mean TP treatment duration was 19 ± 7 months. TP withdrawal was due to poor compliance and side effects (fever and osteo-muscular pain) in two and three patients, respectively. After 12 and 24 months, BMD significantly increased at lumbar (+ 19% and 22%) and femoral sites (+ 13% and 13%). Osteocalcin and cross-laps levels increased after 12 and 24 months (+ 225 and + 54.2%; + 159 and 141%, respectively). No new fractures were detected during TP treatment. Baseline VAS score values (3 ± 3) did not significantly change after 12 and 24 months (3 ± 3 and 2 ± 3, respectively). Five out of eleven patients developed side effects. TP might be an effective treatment for TM-associated osteoporosis since it improves BMD, especially at the lumbar spine, and prevents fragility fractures. TM patients may have a higher frequency of side effects, especially muscle and bone pain under TP treatment, as compared to no TM population. Further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.